4591 — Ribomic Share News
0.000.00%
Last trade - 00:00Table: Ribomic -2021/22 parent results
Table: Ribomic -2021/22 parent forecast
Brief: Ribomic Completes IND Submission For Observational Study For Continuous Phase 2 Trial Of RBM-007
Brief: RIBOMIC Inc Provides Update On RBM-007 Program
Table: Ribomic - 9-MTH parent results
Brief: Ribomic Announces Preliminary Topline Data From Phase 2 Trials Of Rbm-007 Eye Disorder Drug
Table: Ribomic - 6-MTH parent results
Table: Ribomic - Q1 parent results
Table: Ribomic -2020/21 parent results
Table: Ribomic - 9-MTH parent results
Table: Ribomic - 6-MTH parent results
Table: Ribomic - Q1 parent results
Table: Ribomic -2019/20 parent results
Brief: Ribomic Enters License Agreement With Aju Pharma For Rbm-007 In Age-Related Macular Degeneration
Table: Ribomic - 9-MTH parent results
Table: Ribomic - 6-MTH parent results
Table: Ribomic - Q1 parent results
Brief: Ribomic Announces Positive Top-Line Results From The Phase 1/2A Clinical Trial Of Rbm-007
Table: Ribomic -2018/19 parent results